In contrast to PYY, GLP-1 has been evaluated extensively in large clinical studies and serves as the foundation for several approved treatments for T2D and obesity, such as liraglutide and semaglutide. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.